Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
David L. MahoneyDirector | Corcept TherapeuticsCORT | Open-market sale | 06/17 | 06/18 | 20,000 sh | $84.53 | $1,690,600 | −43.3% |
Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 06/16 | 06/18 | 10,000 sh2 trades | $83.20avg. | $832,024.24 | −0.9% | |
Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 06/15 | 06/17 | 40,000 sh4 trades | $81.15avg. | $3,245,873.95 | −71.3% | |
Guyer WilliamChief Development Officer | Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 06/02 | 06/04 | 20,000 sh | $70.60 | $1,412,000 | −83.4% |
Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 06/01 | 06/03 | 40,000 sh | $70.00 | $2,800,000 | −72.4% | |
SEE REMARKS | Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 06/01 | 06/03 | 25,000 sh2 trades | $70.21avg. | $1,755,265.84 | −73.6% |
Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 06/01 | 06/02 | 12,837 sh | $69.74 | $895,252.38 | −0.5% | |
SEE REMARKS | Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 05/27 | 05/29 | 75,000 sh2 trades | $65.59avg. | $4,918,885.75 | −89.3% |
Lyon Joseph DouglasSEE REMARKS | Corcept TherapeuticsCORT | Open-market sale | 05/27 | 05/29 | 5,000 sh | $65.00 | $325,000 | −44.5% |
Guyer WilliamChief Development Officer | Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 05/05 | 05/07 | 20,000 sh | $51.83 | $1,036,600 | −90.0% |
Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 05/01 | 05/05 | 40,000 sh | $50.10 | $2,004,000 | −1.4% | |
Guyer WilliamChief Development Officer | Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 04/07 | 04/08 | 20,000 sh | $40.97 | $819,400 | −90.0% |
Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 03/25 | 03/27 | 26,198 sh | $50.07 | $1,311,733.86 | −0.9% | |
Guyer WilliamChief Development Officer | Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 03/20 | 03/24 | 11,767 sh | $36.01 | $423,729.67 | −84.1% |
Corcept TherapeuticsCORT | Open-market buy | 03/17 | 03/19 | 100,000 sh2 trades | $33.14avg. | $3,313,562.08 | +9.6% | |
Guyer WilliamChief Development Officer | Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 03/04 | 03/06 | 8,233 sh | $35.99 | $296,305.67 | −78.7% |
Guyer WilliamChief Development Officer | Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 02/03 | 02/05 | 20,000 sh | $40.87 | $817,400 | −94.2% |
Guyer WilliamChief Development Officer | Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 01/06 | 01/08 | 20,000 sh | $35.18 | $703,600 | −94.2% |
Chief Development Officer | Corcept TherapeuticsCORT | Open-market sale10b5-1 plan · Amendment | 25/11/25–25/12/02 | 25/12/03 | 24,500 sh3 trades | $80.23avg. | $1,965,581.2 | No record |
Corcept TherapeuticsCORT | Open-market sale10b5-1 plan | 25/12/01 | 25/12/03 | 40,000 sh | $79.77 | $3,190,800 | −1.5% |
